The antibody catabolism suggested in the model corroborates the observed results of non-linear pharmacokinetic (PK) profiles for trastuzumab in a clinical study of patients with HER2-overexpressing metastatic breast cancers [40], as well as for MEDI4276 in a clinical study of patients with HER2+ advanced breast or gastric cancer [53]. Here, ERBB2 is linked to gastric cancer.